Clinical comparison between ductal carcinoma in situ and ductal carcinoma in situ with microinvasion
Liu Weixin, Wang Shulian, Tang Yu, Jing Hao, Wang Jianyang, Zhang Jianghu, Jin Jing, Song Yongwen, Wang Weihu, Liu Yueping, Fang Hui, Ren Hua, Qi Shunan, Lu Ningning, Tang Yuan, Li Ning, Li Yexiong
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing 100021,China
Abstract：Objective To analyze the differences in the treatment patterns,clinical characteristics,treatment outcomes and prognostic factors between breast cancer patients with ductal carcinoma in situ (DCIS) and ductal carcinoma in situ with microinvasion (DCIS-MI).Methods Clinical data of 866 female patients including 631 DCIS cases and 235 DCIS-MI cases treated in our institution between 1999 and 2013 were retrospectively analyzed. The local control (LC),disease-free survival (DFS) and overall survival (OS) rates were calculated by Kaplan-Meier survival analysis. The prognostic factors were identified by Log-rank test. Results Similar LC,DFS and OS rates were obtained between two groups (all P>0.05). The univariate analysis demonstrated that Her-2-positive patients had worse OS and DFS than Her-2-negative counterparts. Patients undergoing breast-conserving surgery without radiotherapy had lower LC and DFS rates compared with those receiving radical mastectomy. Conclusions DCIS and DCIS-MI patients have similar clinical prognosis in terms of OS,LC and DFS. Her-2 positive is an unfavorable prognostic factor for DFS and OS. The LC and DFS rates in the breast-conserving surgery alone group are worse than those in the mastectomy group.
Liu Weixin,Wang Shulian,Tang Yu et al. Clinical comparison between ductal carcinoma in situ and ductal carcinoma in situ with microinvasion[J]. Chinese Journal of Radiation Oncology, 2020, 29(3): 187-192.
[1] Olivotto I,Levine M. Care SCoCPGft. Cancer ToB:clinical practice guidelines for the care and treatment of breast cancer:the management of ductal carcinoma in situ (summary of the 2001 update)[J]. Canadian Med Associat J,2001,165(7):912-913.
[2] Shatat L,Gloyeske N,Madan R,et al. Microinvasive breast carcinoma carries an excellent prognosis regardless of the tumor characteristics[J]. Human Pathol,2013,44(12):2684-2689. DOI:10.1016/j.humpath.2013.07.010.
[3] Matsen CB,Hirsch A,Eaton A,et al. Extent of microinvasion in ductal carcinoma in situ is not associated with sentinel lymph node metastases[J]. Ann Surg Oncol,2014,21(10):3330-3335. DOI:10.1245/s10434-014-3920-2.
[4] Parikh RR,Haffty BG,Lannin D,et al. Ductal carcinoma in situ with microinvasion:prognosticimplications,long-term outcomes,and role of axillary evaluation[J]. Int J Radiat Oncol Biol Phys,2012,82(1):7-13.
[5] Sopik V,Sun P,Narod SA. Impact of microinvasion on breast cancer mortality in women with ductal carcinoma in situ[J]. Breast Cancer Res Treat,2018,167(3):787-795. DOI:10.1007/s10549-017-4572-2.
[6] Zavagno G,Belardinelli V,Marconato R,et al. Sentinel lymph node metastasis from mammary ductal carcinoma in situ with microinvasion[J]. Breast,2007,16(2):146-151.
[7] de Mascarel I,MacGrogan G,Mathoulin-Pelissier S,et al. Breast ductal carcinoma in situ with microinvasion:a definition supported by a long-term study of 1248 serially sectioned ductal carcinomas[J]. Cancer,2002,94(8):2134-2142.
[8] Trentin C,Dominelli V,Maisonneuve P,et al. Predictors of invasive breast cancer and lymph node involvement in ductal carcinoma in situ initially diagnosed by vacuum-assisted breast biopsy:experience of 733 cases[J]. Breast,2012,21(5):635-640. DOI:10.1016/j.breast.2012.06.009.
[9] Al Nemer AM. Histologic factors predicting invasion in patients with ductal carcinoma in situ (DCIS) in the preoperative core biopsy[J]. Pathol Res Pract,2017,213(5):429-434. DOI:10.1016/j.prp.2017.02.016.
[10] Kim M,Kim HJ,Chung YR,et al. Microinvasive carcinoma versus ductal carcinoma in situ:a comparison of clinicopathological features and clinical outcomes[J]. J Breast Cancer,2018,21(2):197-205. DOI:10.4048/jbc.2018.21.2.197.
[11] Meurs CJC,van Rosmalen J,Menke-Pluijmers MBE,et al. A prediction model for underestimation of invasive breast cancer after a biopsy diagnosis of ductal carcinoma in situ:based on 2892 biopsies and 589 invasive cancers[J]. Br J Cancer,2018,119(9):1155-1162. DOI:10.1038/s41416-018-0276-6.
[12] Cavaliere A,Scheibel M,Bellezza G,et al. Ductal carcinoma in situ with microinvasion:clinicopathologic study and biopathologic profile[J]. Pathol Res Pract,2006,202(3):131-135.
[13] Sopik V,Sun P,Narod SA. Impact of microinvasion on breast cancer mortality in women with ductal carcinoma in situ[J]. Breast Cancer Res Treat,2018,167(3):787-795. DOI:10.1007/s10549-017-4572-2.
[14] Siziopikou KP,Anderson SJ,Cobleigh MA,et al. Preliminary results of centralized HER-2 testing in ductal carcinoma in situ (DCIS):NSABP B-43[J]. Breast Cancer Res Treat,2013,142(2):415-421. DOI:10.1007/s10549-013-2755-z.
[15] Zhou W,Jirström K,Amini RM,et al. Molecular subtypes in ductal carcinoma in situ of the breast and their relation to prognosis:a population-based cohort study[J]. BMC Cancer,2013,13(1):1-9. DOI:10.1186/1471-2407-13-512.
[16] Wu Q,Li J,Sun S,et al. Breast carcinoma in situ:an observational study of tumor subtype,treatment and outcomes[J]. Oncotarget,2017,8(2):2361-2371. DOI:10.18632/oncotarget.13785.
[17] Park HS,Kim HY,Park S,et al. A nomogram for predicting underestimation of invasiveness in ductal carcinoma in situ diagnosed by preoperative needle biopsy[J]. Breast,2013,22(5):869-873. DOI:10.1016/j.breast.2013.03.009.
[18] Mori M,Tsugawa K,Yamauchi H,et al. Pathological assessment of microinvasive carcinoma of the breast[J]. Breast Cancer,2013,20(4):331-335. DOI:10.1007/s12282-012-0339-0.
[19] Wahedna Y,Evans A,Pinder S,et al. Mammographic size of ductal carcinoma in situ does not predict the presence of an invasive focus[J]. Eur J Cancer,2001,37(4):459-462.
[20] Seo YY,Yoo IR,Park SY,et al. Ductal carcinoma in situ and ductal carcinoma in situ with microinvasion:correlation of FDG uptake with histological and biological prognostic factors[J]. Breast Cancer,2017,24(3):353-361. DOI:10.1007/s12282-016-0710-7.
[21] Hussein H,Chung C,Moshonov H,et al. Evaluation of apparent diffusion coefficient to predict grade,microinvasion,and invasion in ductal carcinoma in situ of the breast[J]. Acad Radiol,2015,22(12):1483-1488. DOI:10.1016/j.acra.2015.08.004.
[22] Yao JJ,Zhan WW,Chen M,et al. Sonographic features of ductal carcinoma in situ of the breast with microinvasion:correlation with clinicopathologic findings and biomarkers[J]. J Ultrasound Med,2015,34(10):1761-1768. DOI:10.7863/ultra.15.14.07059.
[23] Mitchell KB,Lin H,Shen Y,et al. DCIS and axillary nodal evaluation:compliance with national guidelines[J]. BMC Surg,2017,17(1):12. DOI:10.1186/s12893-017-0210-5.
[24] Julien JP,Bijker N,FentimanI S,et al. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ:first results of the EORTC randomised phase Ⅲ trial 10853[J]. Lancet,2000,355(9203):528-533.
[25] Fisher B,Land S,Mamounas E,et al. Prevention of invasive breast cancer in women with ductal carcinoma in situ:an update of the national surgical adjuvant breast and bowel project experience[J]. Semin Oncol,2001(4):400-418.
[26] Houghton J. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK,Australia,and New Zealand:randomized controlled trial[J]. Lancet,2003,362(9378):95-102.
[27] Cutuli B,Fay R,Cohen-Solal-Le Nir C,et al. Ductal carcinoma in situ of the breast. Analysis of 882 cases[J]. Presse Med,2004,33(2):83-89.
[28] Cuzick J,SestakI,Pinder SE,et al. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ:long-term results from the UK/ANZ DCIS trial[J]. Lancet Oncol,2011,12(1):21-29. DOI:10.1016/S1470-2045(10)70266-7.
[29] WapnirI L,Dignam JJ,Fisher B,et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS[J]. J Natl Cancer Inst,2011,103(6):478-488. DOI:10.1093/jnci/djR027.
[30] Allred DC,Anderson SJ,Paik S,et al. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ:a study based on NSABP protocol B-24[J]. J Clin Oncol,2012,30(12):1268-1273.
[31] McCormick B,Winter K,Hudis C,et al. RTOG 9804:a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation[J]. J Clin Oncol,2015,33(7):709-715.
2020, Vol. 29 
